Protein biosynthesis interference in disease /

Protein biosynthesis interference in disease /

Saved in:
Bibliographic Details
Author / Creator:Paley, Elena L.
Imprint:London : Academic Press, 2021.
Description:1 online resource (297 pages)
Language:English
Subject:
Proteins -- Synthesis.
Biosynthesis.
Biosynthesis.
Proteins -- Synthesis.
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/12487973
Hidden Bibliographic Details
ISBN:9780128234860
0128234865
9780128234853
0128234857
Notes:21 Tryptamine content and effects in human and animals.
Description based on print version record.
Summary:Protein Biosynthesis Interference in Disease offers a thorough discussion and overview of protein biosynthesis interference, its mechanisms of action, and influence over disease processes. This book examines the role of protein biosynthesis interference in Alzheimer's and other neurodegenerative conditions, cancer and inflammatory disorders, with specific attention paid to the biochemical dynamics of tryptamine, biogenic amines and aminoacyl-tRNA synthetases in these pathologies. Methods of regulating protein translation and interference mechanisms, including gene therapy, are presented, empowering biochemists, molecular biologists, disease researchers, and health professionals to understand the underlying factors of protein disease and improve patient outcomes.
Other form:Print version: Paley, Elena L. Protein Biosynthesis Interference in Disease San Diego : Elsevier Science & Technology,c2020 9780128234853
Table of Contents:
  • Front Cover
  • Protein Biosynthesis Interference in Disease
  • Copyright Page
  • Contents
  • Preface
  • 1 Introduction
  • 2 Tryptamine in the diet, human microbiome, tRNA aminoacylation-protein biosynthesis, host-microbiota metabolic interactions
  • 2.1 Tryptamine interfere with the tRNA aminoacylation-protein biosynthesis in the model of neurodegeneration
  • 2.2 Tryptamine interfere with serotonin binding to receptors in serotonin syndrome
  • 2.3 Tryptamine in dysbiosis
  • 3 Dimethyltryptamine, methyltryptamine, hallucinations and metals
  • 4 Psychoactive effects and toxicity of tryptamine, N-methyltryptamine (NMT), and N, N-dimethyltryptamine (DMT): quantificat...
  • 5 Tryptamine in renal pathologies and in pregnancy
  • 6 Tryptophanyl-tRNA synthetase (TrpRS) inhibition or TrpRS gene (WARS) mutations and deletion result to TrpRS deficiency an...
  • 7 Tryptamine in liver diseases and alcohol abuse
  • 8 Tryptamine and tyramine in tobacco smoking
  • 9 Tryptamine and other biogenic amines in human vaginal samples
  • 10 Tryptamine and tryptophan in human fecal samples: diet alters tryptamine levels
  • 11 Tryptamine in human noncataractous and cataractous eye lenses
  • 12 Tryptamine toxicity in rats, adrenalectomy, toxicity prevention
  • 13 Microorganisms: the natural producers of tryptamine in food
  • 14 Human gut bacterial sequence associated with Alzheimer's disease and biogenic amines
  • 15 Diseases, factors and conditions associated with Alzheimer's disease (AD) and dementia support a concept that AD is a wi...
  • 15.1 Historical evolution and terminology from 1907 to contemporary
  • 15.2 Senile plaques and neurofibrillary tangles in organs other than brain
  • 15.3 Diseases, factors and conditions associated with Alzheimer's disease and dementia
  • 16 Arterial hypertension is comorbidity in dementia and Alzheimer's disease, tryptamine in metabolic syndrome
  • 17 Whole blood viscosity: biogenic amines, dementia and Alzheimer's disease
  • 18 Tryptamine and aminoacyl-tRNAs in sleep-wake and circadian disruption
  • 19 Senile plaques and/or neurofibrillary tangles in brain of non-demented individuals
  • 20 Historical perspective and future research directions
  • 20.1 On determining the most appropriate test cut-off values for Alzheimer's disease associated sequence (ADAS)-linked tryp...
  • 20.2 Updated hypothesis of tryptamine-induced neurodegeneration: experimental and observational data
  • 20.3 Validation studies and future experiments
  • 20.4 Major challenges for new preclinical and clinical trials
  • 20.5 Tryptamine physiological pathways: tryptamine is a ligand and agonist activating 5H, TAAR1, and AhR receptors
  • 20.6 Linkage of present theory to other theories and the major pathological features of Alzheimer's disease

Similar Items